These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 30712769)
1. Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens. van Griensven J; Diro E Infect Dis Clin North Am; 2019 Mar; 33(1):79-99. PubMed ID: 30712769 [TBL] [Abstract][Full Text] [Related]
2. Clinical aspects of visceral leishmaniasis in HIV infection. Jarvis JN; Lockwood DN Curr Opin Infect Dis; 2013 Feb; 26(1):1-9. PubMed ID: 23221770 [TBL] [Abstract][Full Text] [Related]
3. Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol. Khodabandeh M; Rostami A; Borhani K; Gamble HR; Mohammadi M Parasitol Int; 2019 Oct; 72():101934. PubMed ID: 31129197 [TBL] [Abstract][Full Text] [Related]
4. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure. Eichenberger A; Buechi AE; Neumayr A; Hatz C; Rauch A; Huguenot M; Diamantis-Karamitopoulou E; Staehelin C BMC Infect Dis; 2017 Jan; 17(1):81. PubMed ID: 28095796 [TBL] [Abstract][Full Text] [Related]
5. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009]. Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391 [TBL] [Abstract][Full Text] [Related]
6. High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B. Chappuis F; Alirol E; Worku DT; Mueller Y; Ritmeijer K Antimicrob Agents Chemother; 2011 Jan; 55(1):455-6. PubMed ID: 21078947 [No Abstract] [Full Text] [Related]
7. [Visceral childhood leishmaniasis: diagnosis and treatment]. Prieto Tato LM; La Orden Izquierdo E; Guillén Martín S; Salcedo Lobato E; García Esteban C; García-Bermejo I; Ramos Amador JT An Pediatr (Barc); 2010 May; 72(5):347-51. PubMed ID: 20378427 [TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377 [TBL] [Abstract][Full Text] [Related]
9. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Chappuis F; Sundar S; Hailu A; Ghalib H; Rijal S; Peeling RW; Alvar J; Boelaert M Nat Rev Microbiol; 2007 Nov; 5(11):873-82. PubMed ID: 17938629 [TBL] [Abstract][Full Text] [Related]
10. Visceral leishmaniasis in an infant gorilla (Gorilla gorilla gorilla): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B. Tinoco HP; da Costa MELT; Pessanha AT; Coelho CM; de Carvalho TF; Mol JPDS; Viana AG; Bueno LL; Fujiwara RT; Santos RL J Med Primatol; 2018 Dec; 47(6):416-418. PubMed ID: 29956831 [TBL] [Abstract][Full Text] [Related]
11. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B. Dilber E; Erduran E; Işik Y Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816 [TBL] [Abstract][Full Text] [Related]
13. Visceral leishmaniasis: rapid response to AmBisome treatment. Smith OP; Hann IM; Cox H; Novelli V Arch Dis Child; 1995 Aug; 73(2):157-9. PubMed ID: 7574862 [TBL] [Abstract][Full Text] [Related]
14. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge. Patole S; Burza S; Varghese GM Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662 [TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis: advances in treatment. Maltezou HC Recent Pat Antiinfect Drug Discov; 2008 Nov; 3(3):192-8. PubMed ID: 18991801 [TBL] [Abstract][Full Text] [Related]
16. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Meyerhoff A Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069 [TBL] [Abstract][Full Text] [Related]
17. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Berman JD Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695 [No Abstract] [Full Text] [Related]
18. Visceral leishmaniasis caused by Leishmania infantum in Thailand. Maharom P; Siripattanapipong S; Mungthin M; Naaglor T; Sukkawee R; Pudkorn R; Wattana W; Wanachiwanawin D; Areechokchai D; Leelayoova S Southeast Asian J Trop Med Public Health; 2008 Nov; 39(6):988-90. PubMed ID: 19062685 [TBL] [Abstract][Full Text] [Related]
19. Visceral leishmaniasis in an infant following a holiday trip to Spain. Trück J; Rampton C; Kelly SJ; Kelly D BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25920739 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of visceral leishmaniasis with liposomal amphotericin B. Lagler H; Matt U; Sillaber C; Winkler S; Graninger W Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]